Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization.
OBJECTIVE
To determine the pre-treatment ocular factors significantly associated with the visual outcome 24 months after intravitreal bevacizumab (IVB) for myopic choroidal neovascularization (mCNV).


METHODS
A total of 23 eyes of 23 patients with mCNV were treated with IVB followed by as needed therapy. The efficacy of IVB was evaluated by the best-corrected visual acuity (BCVA) at 24 months after the initial treatment. Forward stepwise multiple linear regression analyses were performed to evaluate the influence of pre-treatment factors on the BCVA and the improvement of the BCVA at 24 months.


RESULTS
The mean pre-IVB BCVA was 0.74 ± 0.30 logarithm of the minimum angle of resolution (logMAR) units, and it improved to 0.43 ± 0.31 logMAR units after 1 month (P < 0.001, paired t-test). The improvement was maintained at 24 months (0.46 ± 0.40, P < 0.005). The mean number of IVB performed during the 24 months was 1.35 ± 0.71. Forward stepwise regression analysis showed that the pre-IVB CNV size (standardized β = 0.52, P < 0.01) and BCVA (standardized β = -0.44, P < 0.05) significantly affected the visual acuity change after 24 months. The CNV size was the only factor that significantly affected the BCVA after 24 months (standardized β=0.56, P < 0.01).


CONCLUSIONS
IVB with as needed therapy for mCNV led to a rapid and sustained visual improvement. Smaller CNV size was a significant prognostic factor that predicts better visual acuity. Patients with lower pre-treatment BCVA had better visual recovery than those with better pre-treatment BCVA, however, this may be due to a ceiling/floor effect.
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
H
H
Nakanishi
A
A
Tsujikawa
Y
Y
Yodoi
Y
Y
Ojima
A
A
Otani
H
H
Tamura
K
K
Yamashiro
S
S
Ooto
N
N
Yoshimura
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D012044:Regression Analysis; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
Br J Ophthalmol. 2003 May;87(5):570-3
12714395
Ophthalmology. 2003 Jul;110(7):1297-305
12867382
Arch Ophthalmol. 2010 Apr;128(4):437-42
20142520
Am J Ophthalmol. 2010 Jan;149(1):140-6
19846061
Am J Ophthalmol. 1971 Jan;71(1 Pt 1):42-53
5099937
Retina. 2009 Sep;29(8):1062-6
19734760
Br J Ophthalmol. 2009 Feb;93(2):150-4
18801766
Graefes Arch Clin Exp Ophthalmol. 2005 Jan;243(1):13-9
15290153
Ophthalmology. 2003 Apr;110(4):667-73
12689884
Retina. 2010 Mar;30(3):485-90
19952993
Br J Ophthalmol. 2009 Apr;93(4):448-51
19091851
Am J Ophthalmol. 1981 Feb;91(2):177-83
6162388
Jpn J Ophthalmol. 2009 Jul;53(4):389-95
19763757
Am J Ophthalmol. 2009 Jan;147(1):94-100.e1
18774550
Graefes Arch Clin Exp Ophthalmol. 2010 Apr;248(4):543-50
20111971
Am J Ophthalmol. 2004 Sep;138(3):434-8
15364227
Br J Ophthalmol. 2010 Jul;94(7):864-70
19965833
Am J Ophthalmol. 2009 Jan;147(1):84-93.e1
18774547
Bull Soc Belge Ophtalmol. 2009;(312):17-27
19927486
Am J Ophthalmol. 2009 Sep;148(3):396-408
19427991
Int Ophthalmol. 2001;24(5):249-55
14531625
Graefes Arch Clin Exp Ophthalmol. 2006 Nov;244(11):1474-9
16628418
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004765
16235380
Br J Ophthalmol. 2007 Oct;91(10):1318-22
17537784
Ophthalmology. 2002 Apr;109(4):712-9
11927428
Eye (Lond). 2009 Nov;23(11):2042-5
19151652
Retina. 1992;12(2):127-33
1439243
Am J Ophthalmol. 2007 Dec;144(6):850-857
17949673
Retina. 2010 May;30(5):739-47
20038860
Am J Ophthalmol. 2004 Oct;138(4):602-7
15488787
Retina. 2010 Mar;30(3):418-24
20094012
Ophthalmology. 2007 Feb;114(2):246-52
17270674